The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
Insulin resistance is documented in clamp studies in 75% of women with polycystic ovary syndrome (PCOS). Although it is not included in the diagnostic criteria of PCOS, there is a crucial role of this metabolic impairment, which along with hormonal abnormalities, increase each other in a vicious cir...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/8/4334 |
| _version_ | 1797434546785878016 |
|---|---|
| author | Krzysztof Bednarz Karolina Kowalczyk Marlena Cwynar Dominika Czapla Wiktor Czarkowski Dominika Kmita Artur Nowak Paweł Madej |
| author_facet | Krzysztof Bednarz Karolina Kowalczyk Marlena Cwynar Dominika Czapla Wiktor Czarkowski Dominika Kmita Artur Nowak Paweł Madej |
| author_sort | Krzysztof Bednarz |
| collection | DOAJ |
| description | Insulin resistance is documented in clamp studies in 75% of women with polycystic ovary syndrome (PCOS). Although it is not included in the diagnostic criteria of PCOS, there is a crucial role of this metabolic impairment, which along with hormonal abnormalities, increase each other in a vicious circle of PCOS pathogenesis. Insulin resistance in this group of patients results from defects at the molecular level, including impaired insulin receptor-related signaling pathways enhanced by obesity and its features: Excess visceral fat, chronic inflammation, and reactive oxygen species. While lifestyle intervention has a first-line role in the prevention and management of excess weight in PCOS, the role of anti-obesity pharmacological agents in achieving and maintaining weight loss is being increasingly recognized. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) not only act by reducing body weight but also can affect the mechanisms involved in insulin resistance, like an increasing expression of glucose transporters in insulin-dependent tissues, decreasing inflammation, reducing oxidative stress, and modulating lipid metabolism. They also tend to improve fertility either by increasing LH surge in hypothalamus-pituitary inhibition due to estrogen excess connected with obesity or decreasing too high LH levels accompanying hyperinsulinemia. GLP1-RAs seem promising for effective treatment of obese PCOS patients, acting on one of the primary causes of PCOS at the molecular level. |
| first_indexed | 2024-03-09T10:33:53Z |
| format | Article |
| id | doaj.art-2de9623f834948b48a847d4f25770381 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T10:33:53Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-2de9623f834948b48a847d4f257703812023-12-01T21:04:15ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-04-01238433410.3390/ijms23084334The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary SyndromeKrzysztof Bednarz0Karolina Kowalczyk1Marlena Cwynar2Dominika Czapla3Wiktor Czarkowski4Dominika Kmita5Artur Nowak6Paweł Madej7Department of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandDepartment of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandDepartment of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandDepartment of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandDepartment of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandDepartment of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandGynecological and Obstetrician Polyclinic, District Hospital, 15-435 Białystok, PolandDepartment of Gynecological Endocrinology, Medical University of Silesia in Katowice, 40-752 Katowice, PolandInsulin resistance is documented in clamp studies in 75% of women with polycystic ovary syndrome (PCOS). Although it is not included in the diagnostic criteria of PCOS, there is a crucial role of this metabolic impairment, which along with hormonal abnormalities, increase each other in a vicious circle of PCOS pathogenesis. Insulin resistance in this group of patients results from defects at the molecular level, including impaired insulin receptor-related signaling pathways enhanced by obesity and its features: Excess visceral fat, chronic inflammation, and reactive oxygen species. While lifestyle intervention has a first-line role in the prevention and management of excess weight in PCOS, the role of anti-obesity pharmacological agents in achieving and maintaining weight loss is being increasingly recognized. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) not only act by reducing body weight but also can affect the mechanisms involved in insulin resistance, like an increasing expression of glucose transporters in insulin-dependent tissues, decreasing inflammation, reducing oxidative stress, and modulating lipid metabolism. They also tend to improve fertility either by increasing LH surge in hypothalamus-pituitary inhibition due to estrogen excess connected with obesity or decreasing too high LH levels accompanying hyperinsulinemia. GLP1-RAs seem promising for effective treatment of obese PCOS patients, acting on one of the primary causes of PCOS at the molecular level.https://www.mdpi.com/1422-0067/23/8/4334polycystic ovary syndrome (PCOS)insulin resistance (IR)glucagon-like peptide-1 receptor agonists (GLP-1RAs)obesityinflammationoxidative stress |
| spellingShingle | Krzysztof Bednarz Karolina Kowalczyk Marlena Cwynar Dominika Czapla Wiktor Czarkowski Dominika Kmita Artur Nowak Paweł Madej The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome International Journal of Molecular Sciences polycystic ovary syndrome (PCOS) insulin resistance (IR) glucagon-like peptide-1 receptor agonists (GLP-1RAs) obesity inflammation oxidative stress |
| title | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome |
| title_full | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome |
| title_fullStr | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome |
| title_full_unstemmed | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome |
| title_short | The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome |
| title_sort | role of glp 1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome |
| topic | polycystic ovary syndrome (PCOS) insulin resistance (IR) glucagon-like peptide-1 receptor agonists (GLP-1RAs) obesity inflammation oxidative stress |
| url | https://www.mdpi.com/1422-0067/23/8/4334 |
| work_keys_str_mv | AT krzysztofbednarz theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT karolinakowalczyk theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT marlenacwynar theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT dominikaczapla theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT wiktorczarkowski theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT dominikakmita theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT arturnowak theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT pawełmadej theroleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT krzysztofbednarz roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT karolinakowalczyk roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT marlenacwynar roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT dominikaczapla roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT wiktorczarkowski roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT dominikakmita roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT arturnowak roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome AT pawełmadej roleofglp1receptoragonistsininsulinresistancewithconcomitantobesitytreatmentinpolycysticovarysyndrome |